TWEET by @CellCentric
Many thanks to @AsanganiLab @CD_AACR View: p300/CBP inhibition, CCS1477. A novel therapeutic approach for AR-addicted advanced prostate cancer. cancerdiscovery.aacrjournals.org/content/11/5/1… pic.twitter.com/8bD3nQbRNl
TWEET by @CellCentric
CCS1477 pivotal publication now in final form and in print in Cancer Discovery. First-in-class p300/CBP inhibitor. See: cancerdiscovery.aacrjournals.org/content/11/5/1… pic.twitter.com/bNeLXdGfDl
TWEET by @CellCentric
IND open: CCS1477 solid tumour clinical trials expanding into the US, building on the dose escalation & schedule setting carried out in the UK pic.twitter.com/hS3rEwIQ1g
TWEET by @CellCentric
Delighted that Gill has joined the expanding clin ops team. CellCentric’s CCS1477 is the lead p300/CBP inhibitor drug in clinical trials. pic.twitter.com/GkE40XFwGc
TWEET by @CellCentric
AACR 2021 online. CCS1477 was presented as a New Drug on the Horizon in 2019, Atlanta. Now in multiple strands of clinical trials. #AACR2021 pic.twitter.com/hj59FDLuUl
TWEET by @CellCentric
Targeting p300/CBP to treat cancer continues to gain interest. CellCentric’s first-in-class inhibitor CCS1477 in mutliple strands of clinical evaluation. pic.twitter.com/FQoU7jf7DW
